Cholangitis Therapeutics Market

Global Cholangitis Therapeutics Market: Overview

Cholangitis is an infection of the biliary tract that leads to significant mortality and morbidity. It is a bacterial infection that occurs when the bile duct that carries bile from the liver to the intestine and gallbladder is blocked by a tumor or gallstone. Bile is a liquid generated by the liver for the digestion of food. Abdominal pain, jaundice, fever, and low blood pressure are some of the symptoms of cholangitis. The presence of pancreatic cancer slightly increases the risk of cholangitis. Several factors lead to the development of cholangitis. They include strictures or blockage of bile duct system, presence of gall stones, swelling of the pancreas, and blood stream infections.  Diagnosis and treatment of the infection at an early stage are very important. People above the age of 60 are more prone to this infection.

Global Cholangitis Therapeutics Market: Key Trends

The cholangitis therapeutics market is expected to expand at a rapid pace. Increase in the geriatric population, changes in lifestyle, and increase in health care awareness are some of the important factors driving the growth of the market. Improvement in health care policies leads to an increase in the affordability of various health care treatments. This, in turn, has increased the life expectancy of the population. The population above the age of 65 years usually suffer from various health disorders. Thus, an increase in the geriatric population globally augments the cholangitis therapeutics market. Moreover, a large number of drug candidates are at different stages of clinical trial approval in the U.S. and Europe. The anticipated launch and commercialization of these products is likely to fuel the cholangitis therapeutics market during the forecast period. However, the delayed diagnosis of cholangitis is a key restarting factor for the cholangitis therapeutics market.

Global Cholangitis Therapeutics Market: Segmentation

The global cholangitis therapeutics market can be segmented based on type of cholangitis, drug class, distribution channel, and region. In terms of type of cholangitis, the market can be classified into primary slerosing (PSC), secondary (acute) cholangitis, and IgG4-associated cholangitis (IAC). The primary slerosing segment is estimated to dominate the global cholangitis therapeutics market in the next few years, owing to a significant rise in the incidence rate of primary slerosing cholangitis over the last few years. In terms of drug class, the global market can be categorized into carbapenam, aminoglycosides, cephalosporines, beta lactamase inhibitors, and others. Based on distribution channel, the global cholangitis therapeutics market can be divided into hospital pharmacies, retail pharmacies, and online pharmacies.

Global Cholangitis Therapeutics Market: Regional Analysis

In terms of region, the global cholangitis market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America and Europe are anticipated to account for major shares of the global market, due to a large population afflicted with pancreatitis and related bile duct disorders. Moreover, availability of technologically advanced diagnostic tools and systems, high levels of awareness about cholangitis, and well- established health care infrastructure are likely to fuel the market in North America and Europe during the forecast period. The cholangitis therapeutics market in Asia Pacific is expected to expand at a high CAGR during the forecast period, due to a rise in the prevalence of cholangitis in highly populous countries such as India and China, rapidly changing health care systems, government initiatives to improve overall health care, and increased per capita health care expenditure. Moreover, a rise in investments by leading global diagnostics companies and a large base of pharmaceutical companies in the region are likely to contribute to the growth of the market in Asia Pacific in the near future. 

Global Cholangitis Therapeutics Market: Competitive Landscape

Key players operating in the global cholangitis therapeutics market include Dr. Reddy’s laboratories Inc. Pfizer Inc., Novartis AG, Gilead Sciences, Inc., Amneal Pharmaceuticals, Inc., Fresenius Kabi AG, Bayer AG, Par Pharmaceutical Inc., and Merck & Co., Inc..